Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) and ContraFect Corporation (NASDAQ:CFRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
Institutional and Insider Ownership
2.7% of Tetralogic Pharmaceuticals Corp shares are owned by institutional investors. Comparatively, 24.5% of ContraFect Corporation shares are owned by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are owned by company insiders. Comparatively, 9.3% of ContraFect Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
Tetralogic Pharmaceuticals Corp has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, ContraFect Corporation has a beta of -0.86, suggesting that its stock price is 186% less volatile than the S&P 500.
This table compares Tetralogic Pharmaceuticals Corp and ContraFect Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
Valuation & Earnings
This table compares Tetralogic Pharmaceuticals Corp and ContraFect Corporation’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-$21.14 million||($1.76)||-0.01|
|ContraFect Corporation||N/A||N/A||-$28.65 million||($0.49)||-1.97|
ContraFect Corporation is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals Corp, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Tetralogic Pharmaceuticals Corp and ContraFect Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
ContraFect Corporation has a consensus price target of $5.00, indicating a potential upside of 417.76%. Given ContraFect Corporation’s higher possible upside, analysts plainly believe ContraFect Corporation is more favorable than Tetralogic Pharmaceuticals Corp.
Tetralogic Pharmaceuticals Corp beats ContraFect Corporation on 5 of the 9 factors compared between the two stocks.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
ContraFect Corporation Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.